New drug combo before radiation for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage III or IV nasopharyngeal cancer (but not certain early stage IV types).
- You cannot have had any prior treatment for this cancer (like surgery, chemo, or radiation).
- You must have at least one tumor that can be seen on a scan and measured.
- You must be in fairly good health, with normal blood counts, liver and kidney function, and a performance status of 0 or 1 (able to do daily activities).
- You must not have active autoimmune diseases, uncontrolled high blood pressure, serious heart conditions, or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (which helps your immune system fight cancer) to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer (a type of cancer in the upper throat). If you qualify, you would receive this combination treatment as your first therapy for this stage of disease.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial tests a combination of three drugs—an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy—for patients with high-risk, locally advanced nasopharyngeal cancer that has not spread to distant organs. The goal is to see if adding these drugs to standard chemoradiation improves outcomes.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer. The goal is to see if adding these drugs improves the chances of controlling the cancer.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.